Browse by category

According to researcher from Ohio State University Wexner Medical Center in Columbus, prescription for patients who were eligible for metabolic and bariatric surgery (MBS) for glucagon-like peptide-1 receptor agonist (GLP-1 RA) increased from 2018 to 2025, while MBS use decreased beginning in 2023. “To our knowledge, this is the first study to provide evidence that trends in MBS use have not yet stabilised through quarter 3 of 2025,” the researchers noted. “Stratification by

The World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease, to address the growing global health challenge of obesity that affects more than one billion people. In 2024, obesity was associated with 3.7 million deaths worldwide and without decisive action, the number of people with obesity is projected to double by 2030. In September 2025, WHO added GLP-1 ther